Skip to content

Main Navigation

Vor Bio
  • News & Media
  • Publications
  • Join Us
  • Contact
  • Blog
  • Search
  • About Us
    • Overview
    • Vision, Mission, and Values
    • Our People
    • Leadership
    • Board of Directors
    • Scientific & Clinical Advisors
    • Founding Story
  • Approach
    • Overview
    • The Opportunity
    • The Concept
    • The Science
    • Programs
    • Manufacturing
    • Partnerships
  • Platform & Pipeline
    • Overview
    • Our Platform
    • Our Pipeline
  • Patients & Caregivers
    • Overview
    • Our Investigational Treatment Approach
    • Clinical Trials
    • The Patient/Donor Journey
    • Patient Advocacy
  • Medical Professionals
    • Overview
    • Our Investigational Program
    • Clinical Trials
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Analyst Coverage
    • Corporate Governance
    • SEC Filings
    • Contact IR
    • Email Alerts

News Types: Biotech Trade

February 16, 2023 by Jake Robison

Endpoints News: Putting a twist on targeted therapy, Vor Biopharma heralds proof of concept for its gene-edited stem cells

Learn More
January 18, 2023 by Jake Robison

Endpoints News: The conference is back. What about the industry? Taking the biotech pulse at #JPM23

Learn More
January 13, 2023 by Jake Robison

PharmaVOICE: How biotechs can weather the market storm

Learn More
December 7, 2022 by Jake Robison

Boston Globe: Vor Biopharma says first patient given its gene editing therapy for leukemia is in remission

Learn More
September 29, 2022 by Sarah Spencer

Endpoints News: Vor Bio opts to keep manufacturing operations in-house

Learn More
September 30, 2021 by Jason Wertheimer

Cell & Gene Therapy Live: Bolstering Stem Cells Against Off-Target Effects of Cancer Therapies

Learn More
September 10, 2021 by Jason Wertheimer

Fierce Biotech: Vor’s cancer cell therapy gets on FDA fast track ahead of 2022 data drop

Learn More
July 8, 2021 by Jason Wertheimer

Endpoints News: J&J, Sid Mukherjee’s Vor team up to pair bispecifics with engineered stem cells for blood cancer

Learn More
August 7, 2019 by Jason Wertheimer

STAT News: ‘Every man and his dog’ does cell therapy. Vor’s new CEO says the company wants to be different

Learn More

Share This Post

Recent Posts

  • A Conversation with a First-Generation Woman in STEM: International Day of Women & Girls in Science February 10, 2023
  • How our unwavering focus on patients helped us weather a tough 2022 for biotech December 28, 2022
  • My journey giving a gift of hope by donating bone marrow December 20, 2022
  • This Thanksgiving and every day, take stock of everything you are grateful for November 23, 2022
  • Teamwork on full display during our clinical manufacturing facility buildout November 9, 2022
  • Lending a Hand, Stepping Up for the Larger Community October 4, 2022
  • Cultivating Company Culture: The Process Behind Vor Bio’s Core Values September 13, 2022
  • The Online Reflection of Vor Bio August 2, 2022
Logo Vor Biopharma White

Follow us on social media:

Twitter LinkedIn
  • About Us
    • Vision, Mission, and Values
    • Our People
    • Leadership
    • Board of Directors
    • Scientific & Clinical Advisors
    • Founding Story
  • Approach
    • The Opportunity
    • The Concept
    • The Science
    • Programs
    • Manufacturing
    • Partnerships
  • Platform & Pipeline
    • Our Platform
    • Our Pipeline
  • Patients & Caregivers
    • Our Investigational Treatment Approach
    • Clinical Trials
    • The Patient/Donor Journey
    • Patient Advocacy
  • Medical Professionals
    • Our Investigational Program
    • Clinical Trials
  • Investors
    • News Releases
    • Events & Presentations
    • Analyst Coverage
    • Corporate Governance
    • SEC Filings
    • Contact IR
    • Email Alerts
  • News & Media
  • Publications
  • Join Us
  • Blog

© 2023 Vor Biopharma

  • Privacy Policy
  • Terms of Use
Recruiting Guidelines

All employment opportunities at Vor Biopharma are managed by our in-house Human Resources Department. Therefore, agency staff and independent recruiters must contact the Human Resources Department directly in order to present candidates or inquire about openings. Please do not contact other Vor Bipharma employees. Your ability to comply with this request will significantly impact any decision we may make about doing business with you.

Please understand that we do not accept unsolicited resumes from any source other than from the candidates themselves. Any agency or independent recruiter must have a signed copy of our agency agreement before presenting candidates. Submission of unsolicited resumes without our signed agreement will not create any implied obligation on our part.

If you wish to be considered for the presentation of candidates, please contact us through careers@vorbio.com. Attach your contact information, your area of specialty, and any marketing information you wish to provide. Someone from the Human Resources Department will contact you directly if there is a business need for your services.